BNBX saw short interest spike to 71% of float before plunging 36% in a single day. Cost to borrow remains extreme above 100%. The stock sits down 29% over the past month.
BNBX closed at $0.52 on April 24, up 4% on the day. The stock has fallen 12% over the past week and 29% over the past month. The life sciences tools company trades without a reported market cap, reflecting its micro-cap status.
Short interest stood at 915,457 shares as of April 23, representing 71% of the free float. The position dropped 36% in a single day after peaking at 1.43 million shares on April 22. That marked the highest level in at least 30 days.
The trajectory has been violent. Short interest sat below 6,400 shares on April 13. It exploded to 242,586 shares on April 14, then continued climbing to the April 22 peak. The one-week change shows a 14% increase despite the sharp recent drop.
FINRA's fortnightly data as of April 15 settlement reported 647,929 shares short with one day to cover.
Cost to borrow reached 101% APR on April 23, down from a peak of 123% on April 20. The metric has climbed 18% over the past week and 93% over the past month. Borrowing costs have been elevated throughout the period, never dipping below 83% in the past 30 days. Early March saw rates around 52% before the sustained climb began.
Utilisation sat at 38% on April 23. It spiked to 73% on April 20 before retreating. The metric has been volatile, touching 55% on April 15 and falling as low as 0.05% on March 31. The 52-week high reached 100%.
Put/call ratio registered 0.19 as of April 24, 2024. That reading sits 1.5 standard deviations below the 20-day mean of 0.19. The 52-week range spans 0.15 to 0.47, placing current sentiment near the low end. Options data is stale, last updated 731 days ago.
Silvermine Capital Advisors took a new 598,557-share position as of March 20, representing 11% of shares outstanding. Off The Chain Capital initiated a 217,840-share stake (3.8%) in the December quarter. Galaxy Group Investments established a 188,210-share position (3.3%) in the same period.
Joshua Kruger, an individual holder, reported 75,303 shares (1.3%) as of December 15. Sabby Management disclosed 54,000 shares (1.0%) despite a 217,840-share change figure in the December quarter, suggesting partial trimming from a larger base.
Geode Capital added 28,211 shares to reach 28,767 shares (0.5%) as of February 27. Vanguard initiated with 16,690 shares (0.3%) in the February quarter. James Haft, an individual, reported 22,590 shares (0.4%) as of February 2.
Net insider activity over the past 90 days showed 13,049 shares purchased with a net value of $110,042. The data is stale, last updated 1,872 days ago in March 2021.
Director Scott Anchin sold 13,049 shares across five transactions on March 10, 2021, at prices between $8.43 and $8.52. The sales totaled $109,042.
Earlier trades included a 75,000-share purchase by 5% shareholder William Montgomery at $5.24 in November 2019, valued at $393,000. Montgomery subsequently sold 205,774 shares across four transactions in 2020 at prices between $7.91 and $8.65.
The company has an earnings event scheduled for April 28, 2026, at 3:00 PM UTC. Prior earnings releases occurred February 13, February 12, December 22, and December 18. The stock's extreme short positioning and high borrowing costs create potential for volatility around the event.
The life sciences tools sector has seen elevated short interest across several names. BNBX ranks in the 6th percentile for short score and 79th percentile for sector score. Days to cover ranks in the 68th percentile, while utilisation sits in the 27th percentile, indicating moderate ease of borrowing despite the high CTB.
See the live data behind this article on ORTEX.
Open BNBX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
